<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971928</url>
  </required_header>
  <id_info>
    <org_study_id>205871</org_study_id>
    <nct_id>NCT04971928</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of GSK3228836 in Adults With Hepatic Impairment and Healthy Matched Control Participants (B-Assured)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of&#xD;
      GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment),&#xD;
      Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic&#xD;
      function as healthy control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">July 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)]</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero (pre-dose) to 24 hours [AUC(0-24)]</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero (pre-dose) to 168 hours [AUC(0-168)]</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of GSK3228836 on Day 8</measure>
    <time_frame>Day 8 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t1/2)</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of Cmax (Tmax)</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase volume of distribution (Vz/F)</measure>
    <time_frame>Up to Day 50 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Participants with Moderate (CP-B) hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with Mild (CP-A) hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3228836</intervention_name>
    <description>GSK3228836 will be administered</description>
    <arm_group_label>Healthy participants</arm_group_label>
    <arm_group_label>Participants with Mild (CP-A) hepatic impairment</arm_group_label>
    <arm_group_label>Participants with Moderate (CP-B) hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;50 Kilogram (kg) and body mass index (BMI) within the range 19 to 40&#xD;
             Kilogram per square meters (kg/m2) (inclusive)&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
          -  Child-Pugh B cirrhosis (moderate hepatic impairment; Part 1) or Child-Pugh A cirrhosis&#xD;
             (mild hepatic impairment; Part 2) or a healthy control participant based on a medical&#xD;
             evaluation including medical history, physical examination (PE), laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed or suspected hepatocellular carcinoma.&#xD;
&#xD;
          -  History of malignancy within the past 5 years except for cancers that are cured by&#xD;
             surgical resection (e.g., skin cancer).&#xD;
&#xD;
          -  History of vasculitis or presence of symptoms and signs of potential vasculitis or&#xD;
             history/presence of other diseases that may be associated with vasculitis condition.&#xD;
&#xD;
          -  Unstable cardiac function or high blood pressure that is not controlled (based on the&#xD;
             investigator's discretion).&#xD;
&#xD;
          -  Any other medical condition which, in the judgment of the investigator and Medical&#xD;
             Monitor, could jeopardize the integrity of the data derived from that participant or&#xD;
             the safety of the participant.&#xD;
&#xD;
          -  Participants who have taken or are currently taking any therapies not allowed by the&#xD;
             protocol.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  History of sensitivity to GSK3228836 or components thereof or a history of drug or&#xD;
             other allergy that, in the opinion of the investigator or Medical Monitor,&#xD;
             contraindicates their participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas C. Marbury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric J Lawitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK3228836</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Child-Pugh B (CP-B) cirrhosis</keyword>
  <keyword>Child-Pugh A (CP-A) cirrhosis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>B-Assured</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

